Higa Tomohiro 4

What Happened Tomohiro Higa, Senior Vice President, Finance of Tenaya Therapeutics (TNYA), was granted equity awards on February 3, 2026. The filing reports: 29,250 shares acquired as restricted stock units (RSUs) at $0.00 and 175,500 derivative securities (an option award) at $0.00. These were grants (transaction code A), so no cash changed hands and this is an award/compensation event rather than a market purchase or sale.

Key Details

• Transaction date: February 3, 2026; Form 4 filed February 5, 2026 (timely filing).
• Grants: 29,250 RSUs @ $0.00; 175,500 derivative securities (option award) @ $0.00.
• Vesting for RSUs: 1/8 of the award vests on August 15, 2026, then 1/8 every six months thereafter (per F2).
• Vesting for option award: 1/48 vests on the one-month anniversary of the grant then 1/48 each month thereafter until fully vested (per F4).
• Footnotes from the filing:
  • F1: RSUs represent the economic equivalent of one share each and will convert to common stock upon vesting.
  • F2: RSU vesting schedule noted above.
  • F3: The filing notes 79,720 shares will be issued upon vesting of RSUs (as part of the awards).
  • F4: Option grant vesting schedule noted above.
• Shares owned after the transaction: not specified in the provided excerpt of the filing.
• Filing timeliness: filed within the normal Form 4 window (not reported late).

Context These awards are compensation-related grants to an executive and do not reflect an open-market purchase or sale. RSUs convert to shares only as they vest, and options create potential future dilution if exercised; neither action immediately increases public float. As with most grants, this is informational about executive compensation and does not, by itself, indicate an intent to buy or sell stock in the market.